Pyc Therapeutics Ltd has released a press release.
First patient dosed in eye disease clinical trial
Filed with ASX ·
6ix hasn’t read this filing yet.
PYC Therapeutics Limited on 6ix
Earlier from PYC Therapeutics
- Placement Supporting Document
- Successful Completion of $30m Placement
- Commencement of First Clinical Study in RP11
- Second Drug Program Progressing to Human Trials
- FDA Clears PYC to Commence First Human Trials in RP11
Later from PYC Therapeutics
- Successful Toxicology Results Pave Way for Phase 2 Trial
- PYC Receives FDA Fast Track Designation
- PYC Increases Ownership of VP-001 Program
- RP11 Clinical Trial Dosing Completed In Patient Cohort 1
- Safety Review Committee Approves Dose Escalation
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics